NCT05283330View on ClinicalTrials.gov

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Cervical CancerProstate Cancer MetastaticBreast CancerColon CancerNSCLCCutaneous Melanoma
Interventions
DRUG

²¹²Pb-DOTAM-GRPR1

²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.

Trial Locations (4)

21061

RECRUITING

Advanced Molecular Imaging and Therapy, Glen Burnie

40536

RECRUITING

UK Markey Cancer Center, Lexington

60611

RECRUITING

Northwestern University Robert H Lurie Medical Research, Chicago

68130

RECRUITING

XCancer Omaha / Urology Cancer Center, Omaha

All Listed Sponsors
lead

Orano Med LLC

INDUSTRY